CIRIUS

Cirius Therapeutics is a clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of liver and metabolic diseases. Cirius is developing MSDC-0602K, a novel, once-daily, oral small molecule for the treatment of nonalcoholic fatty liver disease (NAFLD), which includes nonalcoholic steatohepatitis (NASH), with Type 2 diabetes. MSDC-0602K is designed to selectively modulate the mitochondrial pyruvate carrier (MPC), which mediates at the cellular level the effects of overnutrition, a major cause of NAFLD/NASH and other metabolic disorders... A recently completed Phase 2b clinical trial of MSDC-0602K demonstrated that MSDC-0602K can exert the full beneficial pharmacology of first generation insulin sensitizers without the dose-limiting effects caused by direct activation of PPAR nuclear receptors. Cirius is now planning Phase 3 studies with an emphasis on patients with NAFLD/NASH and Type 2 diabetes.

Also known as: Cirius Therapeutics

Primary location: Kalamazoo United States